Michael A. Weber, MD, George L

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

The Epidemic of the 20th Century: Coronary Heart Disease

Ambulatory Blood Pressure Monitoring in Clinical Practice: A Review

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease Pantelis A. Sarafidis, MD, PhD, Suying Li, PhD, Shu-Cheng Chen, MS, Allan J.

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity Bjarne M. Nes, PhD, Christian R.

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials Mehdi Tahiri, MD, Salvatore Mottillo, MD, Lawrence Joseph, PhD, Louise.

An Unusual Cause of Leg Ulcerations

Long-term Trends in Short-term Outcomes in Acute Myocardial Infarction

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Richard V. Milani, MD, Carl J. Lavie, MD, Robert M

The Systolic Blood Pressure Difference Between Arms and Cardiovascular Disease in the Framingham Heart Study Ido Weinberg, Philimon Gona, Christopher.

Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials Mehdi Tahiri, MD, Salvatore Mottillo, MD, Lawrence Joseph, PhD, Louise.

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction Stein Ørn, MD, John G.F. Cleland, MD, Matti.

Jeffrey H. Barsuk, MD, MS, Elaine R

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure

Bertha Wong, MD, Muhammad M. Mamdani, PharmD, MPH, Catherine H

Introduction The American Journal of Medicine

Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

Nancy M. Albert, PhD, Gregg C. Fonarow, MD, William T

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Sayed H. Naderi, BMedSci, Jonathan P. Bestwick, MSc, David S. Wald, MD

Overview of Current Learning Theories for Medical Educators

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Epidemiology of Myelodysplastic Syndromes

The Epidemic of the 20th Century: Coronary Heart Disease

Suberythemal ultraviolet exposure and reduction in blood pressure

Allison L. Ruff, MD, Kathryn Teng, MD, Bo Hu, PhD, Michael B

Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction Victoria Hamill, PhD, Ian Ford, PhD, Kim Fox, MD,

Muhammad Amer, MD, MHS, FACP, Rehan Qayyum, MD, MHS

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

TIA for the Internist The American Journal of Medicine

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Gout in African Americans

Treatment of hepatitis C

Personalized Activity Intelligence (PAI) for Prevention of Cardiovascular Disease and Promotion of Physical Activity Bjarne M. Nes, PhD, Christian R.

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

When Guidelines Cause Hypertension

The Natural Course of Microalbuminuria among African Americans with Type 2 Diabetes: A 3-Year Study Mohamed G. Atta, MD, MPH, Kesha Baptiste-Roberts,

Salt and Hypertension American Journal of Kidney Diseases

Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An INVEST Substudy Scott J. Denardo, MD, Yan Gong, PhD, Wilmer.

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Volume 81, Issue 6, Pages (March 2012)

Elevated High-Density Lipoprotein Cholesterol Is Associated with Hyponatremia in Hypertensive Patients Ariel Israel, MD, PhD, Ehud Grossman, MD The.

Nilay S. Shah, MD, MPH, David Leonard, PhD, Carrie E

Insomnia in the Elderly: Cause, Approach, and Treatment

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

To Reduce Stroke with PFO Closure, Respect the Shunt

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

John-Michael Gamble, BScPharm, MSc, Dean T. Eurich, PhD, Thomas J

Sodium Intake and Mortality in the NHANES II Follow-up Study

A Post-cure Complication

Jeffrey H. Barsuk, MD, MS, Elaine R

Primary Care Management of Skin Abscesses Guided by Ultrasound

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

Falls in Older Adults: Risk Assessment, Management and Prevention

Emily G. McDonald, MD, MSc, Ramy R. Saleh, MD, Todd C. Lee, MD, MPH

Matthew W. Martinez, MD, Keith G. Rasmussen, MD, Paul S

Toward a More Responsible News Media

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States Ahmet Ergin, MD, PhD, MPH, Paul.

Presentation transcript:

Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension Michael A. Weber, MD, George L. Bakris, MD, Allen Hester, PhD, Matthew R. Weir, MD, Tsushung A. Hua, PhD, Dion Zappe, PhD, Bjorn Dahlof, MD, Eric J. Velazquez, MD, Bertram Pitt, MD, Kenneth Jamerson, MD The American Journal of Medicine Volume 126, Issue 6, Pages 501-508 (June 2013) DOI: 10.1016/j.amjmed.2013.01.007 Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 1 Disposition of patients in the ACCOMPLISH trial according to their achieved systolic blood pressures. SBP=systolic blood pressure. The American Journal of Medicine 2013 126, 501-508DOI: (10.1016/j.amjmed.2013.01.007) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 2 Comparisons of clinical outcomes among groups of patients categorized by their achieved systolic blood pressures in the ACCOMPLISH trial. Hazard ratios were derived by Cox regression analysis. Definitions of the primary end point, clinical coronary events, and increased serum creatinine are given in the “Materials and Methods” section. BP=blood pressure; CI=confidence interval; CV=cardiovascular; HR=hazard ratio; MI=myocardial infarction. The American Journal of Medicine 2013 126, 501-508DOI: (10.1016/j.amjmed.2013.01.007) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 3 Event rates (per 1000 patient years) for major clinical outcomes in patients in ACCOMPLISH categorized according to their achieved systolic blood pressures. The P values for differences between adjacent groups are shown only if they are significant, but are shown for all comparisons between the>140 mm Hg group and each of the other groups. The definition of the primary end point is given in the “Materials and Methods” section. The American Journal of Medicine 2013 126, 501-508DOI: (10.1016/j.amjmed.2013.01.007) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 4 Event rates (per 1000 patient years) for major clinical outcomes in patients in ACCOMPLISH categorized according to their achieved systolic blood pressures. The P values for differences between adjacent groups are shown only if they are significant, but are shown for all comparisons between the>140 mm Hg group and each of the other groups. The definitions of clinical coronary events and increased serum creatinine are given in the “Materials and Methods” section. The American Journal of Medicine 2013 126, 501-508DOI: (10.1016/j.amjmed.2013.01.007) Copyright © 2013 Elsevier Inc. Terms and Conditions